




Figure 1: Examples of the extent of angiogenic sprouting in the rat aortic angiogenesis assay.




Figure 2: Extent of angiogenesis in aortic cultures.

2/92




Figure 3: Median tumour volumes of untreated controls, PI-88, analogue PG524 and selected test compounds.




Figure 4: Percent tumour growth inhibition (%TGI) data from tumour bearing mice treated with PI-88, analogue PG524 and selected test compounds.




Figure 5: Examples of test compounds blocking the formation of lung colonies (dark spots) of B16F1 melanoma cells in mice.

4/92




Figure 6: Metastatic nodule in mice treated with PI-88 and the selected compounds.




Figure 7: Percent tumour growth inhibition (%TGI) data from the colorectal cancer HT29 xenograft model.

5/92




Figure 8: Effect of test compounds on the cell-to-cell transmission of HSV.

6/92





Figure 9: Effect of test compounds on the binding of HSV virions to the cells.

Figure 10:



8/92







Figure 11:



10/92



11/92



6

12/92






Figure 12:

13/92




9


14/92




15/92




16/92



17/92



18/92



19/92




Figure 14:

20/92







Figure 15:






23/92


Figure 16:



24/92



25/92




26


27

26/92


Figure 17:



27/92




28/92




29/92


Figure 18:




30/92



31/92




32/92





33/92


Figure 19:



34/92




35/92




36/92


Figure 20:




37/92



38/92




39/92




40/92


Figure 21:




41/92



42/92




54




55

43/92





44/92


Figure 22:





45/92



46/92



47/92













Figure 24:








52/92



53/92



54/92






Figure 26:




56/92




57/92

Figure 27:




58/92



82

59/92



83

60/92

Figure 28:






Figure 29:




63/92



90


SUBSTITUTE SHEET (RULE 26) RO/AU

91




91

92




65/92


Figure 30:





66/92




67/92



68/92




69/92




100


70/92




71/92



72/92




73/92





74/92


Figure 33:




75/92



76/92



77/92



78/92







Figure 35:




79/92



121




122




81/92

Figure 36:




82/92





83/92


Figure 37:




84/92




85/92




86/92



87/92



88/92



89/92







Figure 39:



91/92



142



141

Figure 40:

92/92

